cagrilintide plus retatrutide Cagrilintide, Tirzepatide, and Peptides: Comparing Metabolic Mechanisms CagriSema vs Retatrutide 2026: Approval

DSIP A naturally occurring neuropeptide first isolated during slow-wave sleep, researched for sleep regulation, stress responses, pain perception, and potential applications in depression and substance withdrawal

In the 2025 human IV infusion pilot, two adults receiving 10-20 mg doses showed no measurable changes in cardiac, hepatic, renal, thyroid, or glucose markers

Your Bowery Clinic doctor reviews your health history, starts you at an appropriate dose, and adjusts your protocol to keep treatment safe and aligned with your goals

Contraindications: BPC-157 therapy is not appropriate for patients with active cancer, during pregnancy or breastfeeding, or for those on blood thinners (anticoagulants) without provider clearance

This isn't a suggestion

FAQ Is BPC-157 FDA approved